Please login to the form below

Not currently logged in
Email:
Password:

Correction: Prexige suspended in UK, Germany and Austria

PMLive news article correction: Prexige suspended in UK, Germany and Austria

We would like to correct an article which appeared in the December 2007 issue of Pharmaceutical Marketing referring to the suspension of the arthritis drug Prexige (lumiracoxib).

In this article, we referred to this being a Bayer product; this is not the case. We would like to apologise to Bayer for our mistake and have corrected the story online.

The corrected story can be found here

11th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics